Nectar Lifescience Ltd
NSE: NECLIFE BSE: 532649
₹13.87
(3.97)%
Mon, 02 Feb 2026, 02:01 pm
Market Cap3.01B
PE Ratio-
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KAnalysis
dividend
- Nectar Lifesciences is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
- No need to calculate the sustainability of Nectar Lifesciences's dividends as it is not paying a notable one for India.
- Nectar Lifesciences is not paying a notable dividend for India, therefore no need to check if the payments are stable.
- Nectar Lifesciences's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Nectar Lifesciences's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- Nectar Lifesciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Nectar Lifesciences is profitable, therefore cash runway is not a concern.
- Nectar Lifesciences is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (33.8%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 2.2x debt.
- Nectar Lifesciences's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (95.6% vs 69.6% today).
- Interest payments on debt are not well covered by earnings (EBIT is 2.7x annual interest expense, ideally 3x coverage).
- Nectar Lifesciences's level of debt (69.6%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Nectar Lifesciences board of directors is about average.
- Sanjiv's compensation has been consistent with company performance over the past year, both up more than 20%.
- Sanjiv's remuneration is higher than average for companies of similar size in India.
misc
- Nectar Lifesciences is not covered by any analysts.
- Nectar Lifesciences has significant price volatility in the past 3 months.
past
- Nectar Lifesciences has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Nectar Lifesciences's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- Nectar Lifesciences's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
- Nectar Lifesciences used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Nectar Lifesciences has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Nectar Lifesciences's 1-year earnings growth is negative, it can't be compared to the IN Pharmaceuticals industry average.
value
- Nectar Lifesciences's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Nectar Lifesciences's share price is below the future cash flow value, and at a substantial discount (> 40%).
- Nectar Lifesciences is good value based on assets compared to the IN Pharmaceuticals industry average.
- Nectar Lifesciences is good value based on earnings compared to the IN Pharmaceuticals industry average.
- Nectar Lifesciences is good value based on earnings compared to the India market.
- 532649 outperformed the Market in India which returned -14.5% over the past year.
- BSE:532649 is up 38.9% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:532649 is up 38.9% outperforming the market in India which returned 8% over the past month.
- 532649 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800